{
  "id": 14701203,
  "title": "Recursion Announces Pricing of $200 Million Underwritten Offering of Class A Common Stock",
  "url": "https://urgent.news/2026/10/15/recursion-announces-pricing-of-200-million-underwritten-offering-of",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-15T12:52:46.000Z",
  "source": {
    "name": "Financial Post",
    "slug": "financial-post",
    "url": "https://financialpost.com/globe-newswire/recursion-announces-pricing-of-200-million-underwritten-offering-of-class-a-common-stock"
  },
  "original_language": "en",
  "account": null,
  "summary": "Salt Lake City, UT, Oct. 15, 2026 (GLOBE NEWSWIRE) — Recursion Pharmaceuticals, Inc. (“Recursion”) (NASDAQ: RXRX), a leading clinical-stage company pioneering AI-enabled drug discovery and development decoding biology to radically improve lives, today announced the pricing of an underwritten offering of 61,540,000 shares of its Class A common stock at a price of $3.25 per […]",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}